Topiramate’s effectiveness on weight reduction and metabolic syndrome in obese patients with schizophrenia and schizoaffective

Phase 3

• Conditions: Schizophrenia,Schizoaffective.

• Registration Number: IRCT20210622051665N1
• Lead Sponsor: niversity of social welfare and rehabilitation sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 30 August 2021

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

Age between 18 to 65 years
BMI above 27
Patients with schizophrenia or schizoaffective disorder receiving a second-generation antipsychotic drug
Obtaining informed consent from the patient and the patient's legal guardian

Exclusion Criteria

Diabetis
Pregnancy or breastfeeding
Patients with heart failure
Patients with kidney disease
Hypersensitivity to topiramate

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
BMI>27. Timepoint: before study and in weeks 4,8 and 12. Method of measurement: measure height and weight.;Measure abdominal circumference. Timepoint: before study and in weeks 4,8 and 12. Method of measurement: Tape meter.;FBS. Timepoint: before the study and in weeks 4,8 and 12. Method of measurement: Blood sample and lab result.;Total cholesterol. Timepoint: before the study and in weeks 4,8 and 12. Method of measurement: Blood sample and lab result.;Triglyceride. Timepoint: before the study and in weeks 4,8 and 12. Method of measurement: Blood sample and lab result.